“Mylan had no presence in Romania, so that our established pharmaceuticals division of Abbott became Mylan,” said Adrian Grecu, general manager of Mylan EPD.
Adrian Grecu was appointed general manager of Abbott Products Romania in December 2011 and says that “for the time being” he will continue to run this entity.
He started his term in Romania after international experience. He coordinated two company integrations, with the most complicated one being that of India’s Piramal into Abbott’s mature drug division. About the current situation of Romania, he says one cannot speak of an integration in the true sense of the word.
Globally, Mylan has a 1,400-product portfolio covering all the therapeutic areas. Locally, 130 people work for Mylan.
Mylan ranks fourth among the world’s biggest generics players, after Teva, Sandoz and Actavis. While Sandoz and Actavis have production facilities in Romania, Teva and Mylan do not have such facilities locally.
In 2014, Abbott generated revenue worth RON178 million (EUR40 million) in Romania, according to Cegedim data quoted by Adrian Grecu.
(English version by Catalina Apostoiu)